Surgical Research Unit, Department of Surgery, Geneva University Hospital, Switzerland.
Transplantation. 2010 Sep 27;90(6):597-603. doi: 10.1097/TP.0b013e3181eb2e8c.
Xenotransplantation carries inherent risks of infectious disease transmission to the recipient and even to society at large, and it should only be carried out with strict regulation and oversight. In collaboration with the International Xenotransplantation Association, the University Hospital Geneva, and the World Health Organization, an international inventory has been established (www.humanxenotransplant.org) aiming to collect basic data on all types of currently ongoing or recently performed xenotransplantation procedures in humans.
We collected information from publications in scientific journals, presentations at international congresses, the internet, and declarations of International Xenotransplantation Association members on xenotransplantation procedures in humans performed during the past 15 years.
We identified a total of 29 human applications of xenotransplantation, including 7 that were currently ongoing. Procedures involved transplantation of xenogeneic cells, i.e., islets of Langerhans, kidney cells, chromaffin cells, embryonic stem cells, fetal and adult cells from various organs or extracorporeal perfusion using hepatocytes, liver, spleen, or kidney. The treatments were performed in 12 different countries, 9 of them having no national regulation on xenotransplantation.
Several clinical applications of cell xenotransplantation are ongoing around the world, often without any clear governmental regulation. This information should be used to inform national health authorities, healthcare staff, and the public, with the objective of encouraging good practices, with internationally harmonized guidelines and regulation of xenotransplantation.
异种移植具有将传染病传播给受者甚至整个社会的固有风险,因此只能在严格监管下进行。日内瓦大学医院与国际异种移植协会和世界卫生组织合作,建立了一个国际名录(www.humanxenotransplant.org),旨在收集所有类型的人类异种移植程序的基本数据,包括目前正在进行或最近完成的异种移植程序。
我们从科学期刊的出版物、国际大会的演讲、互联网以及国际异种移植协会成员关于过去 15 年在人类中进行的异种移植程序的声明中收集信息。
我们总共确定了 29 个人类异种移植应用,其中 7 个正在进行中。这些程序涉及异种基因细胞的移植,即胰岛、肾细胞、嗜铬细胞、胚胎干细胞、来自各种器官的胎儿和成人细胞,或使用肝细胞、肝、脾或肾进行体外灌注。这些治疗在 12 个不同的国家进行,其中 9 个国家没有关于异种移植的国家监管规定。
世界各地正在进行几种细胞异种移植的临床应用,通常没有任何明确的政府监管。这些信息应被用于告知国家卫生当局、医疗保健人员和公众,以鼓励采用具有国际协调准则和监管的异种移植的良好实践。